Nicholas Fox, MD
Critical Care Medicine · Charleston, SCNPI 1467748483
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,740 of the $87,615 with a category attached, or 63.6%. Actelion Pharmaceuticals US, Inc. accounts for 66.2% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $47,559, more than ten times the $203 reported in 2019. Among critical care medicine clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $215.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$58K
- Merck$10K
- United Therapeutics Corporation$8K
- Intuitive Surgical$7K
- Bayer$732
- GSK$653
- plus $3K from 29 others
What the payments were for
- Consulting fees$8,0359%
- Speaking & faculty fees$55,74064%
- Travel & lodging$7,9959%
- Food & beverage$9,83011%
- Education$6,0157%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 140 | $57,965 |
| Merck | 36 | $10,473 |
| United Therapeutics Corporation | 40 | $7,740 |
| Intuitive Surgical | 14 | $6,801 |
| Bayer | 10 | $732 |
| GSK | 34 | $653 |
| AstraZeneca | 30 | $614 |
| Boehringer Ingelheim | 19 | $583 |
| Insmed, Inc. | 15 | $315 |
| Grifols USA, LLC | 13 | $285 |
| Stryker | 2 | $214 |
| Inari Medical, Inc. | 2 | $205 |
| Mylan Specialty L.p. | 9 | $143 |
| Sanofi | 5 | $139 |
| Harmony Biosciences LLC | 6 | $105 |
| Liquidia Technologies, Inc. | 2 | $103 |
| Regeneron Healthcare Solutions, Inc. | 4 | $93 |
| AbbVie | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Shionogi Inc | 2 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Novartis | 1 | $31 |
| Baxter Healthcare | 1 | $25 |
| Verona Pharma, Inc. | 1 | $24 |
| Haemonetics Corporation | 1 | $22 |
| Resmed Corp | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Pfizer | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Inogen, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$55,315
- OPSUMIT$55,315
- WINREVAIR$9,540
- Da Vinci Surgical System$6,576
- Adempas$600
- FLOWTRIEVER CATHETER, S$343
- CT THROMBECTOMY SYSTEM KIT$343
- TEZSPIRE$127
- TRELEGY ELLIPTA$103
How this compares
$87,615 in reported general payments places this provider in the 90th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 70 | $1,579,177 |
| UptraviSelexipag | 19 | $457,200 |
| OpsumitMacitentan | 35 | $428,888 |
| Orenitram ErTreprostinil Diolamine | 13 | $330,916 |
| AdempasRiociguat | 20 | $282,660 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 209 | $170,120 |
| OfevNintedanib Esylate | 14 | $169,640 |
| Bosentan | 12 | $92,815 |
| AdcircaTadalafil | 12 | $49,039 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 83 | $46,541 |
| Ambrisentan | 17 | $40,201 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $37,866 |
| Tadalafil | 32 | $28,533 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $27,860 |
| EliquisApixaban | 32 | $23,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan | $57,965 | $978,90466 claims |
| BayerAdempas | $732 | $282,66020 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $653 | $245,630359 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $583 | $225,584115 claims |
| United Therapeutics CorporationAdcirca | $7,740 | $49,03912 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $614 | $40,30970 claims |
| PfizerEliquis | $15 | $23,20132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Charleston
- Charlton StrangeCharleston$205K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Christopher GilbertCharleston$44K
- Gregory SquiresCharleston$14K
- John MitchellCharleston$10K
- Luca PaolettiCharleston$5K
- Jennings NestorCharleston$5K
- Tatsiana BeikoCharleston$4K
- Stephen SexauerCharleston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.